BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 18575744)

  • 1. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
    Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY
    Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
    Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T
    Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
    Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prediction synthesis and identification of HLA-A2-restricted cytotoxic T lymphocyte epitopes of the tumor antigen MAGE-n].
    Dong HL; Sui YF; Ye J; Li ZS; Qu P; Zhang XM; Chen GS; Lu SY
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(12):1080-3. PubMed ID: 12899783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
    Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
    Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
    Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry.
    Zhou M; Peng JR; Zhang HG; Wang HX; Zhong ZH; Pan XY; Chen WF; Leng XS
    Immunol Lett; 2005 Jun; 99(1):113-21. PubMed ID: 15885805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
    Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
    Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.
    Toso JF; Oei C; Oshidari F; Tartaglia J; Paoletti E; Lyerly HK; Talib S; Weinhold KJ
    Cancer Res; 1996 Jan; 56(1):16-20. PubMed ID: 8548758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V; Rubio-Godoy V; Dietrich PY; Quiqueres AL; Schnuriger V; Rimoldi D; Liénard D; Speiser D; Guillaume P; Batard P; Cerottini JC; Romero P; Valmori D
    Cancer Res; 2001 Aug; 61(15):5850-6. PubMed ID: 11479225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
    Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
    Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel CD8+ T cell epitope derived from cancer-testis antigen MAGE-4 in oesophageal carcinoma.
    Wu ZY; Gao YF; Wu YH; Liu W; Sun M; Zhai MX; Qi YM; Ye Y
    Scand J Immunol; 2011 Dec; 74(6):561-7. PubMed ID: 21815906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
    Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
    Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
    Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.